Separate indirect from direct design evidence (SIDDE)

Fixed effects model: 

             comparison k  nma direct indir. RoR z p-value
     BZD-long:BZD-short 1 0.97   1.03      .   . .       .
       BZD-long:placebo 1 1.22   1.29      .   . .       .
  BZD-long:propiomazine 0 0.55      .   0.55   . .       .
      BZD-long:zolpidem 0 1.22      .   1.22   . .       .
     BZD-long:zopiclone 3 1.11   1.10      .   . .       .
      BZD-short:placebo 1 1.25   1.25      .   . .       .
 BZD-short:propiomazine 0 0.56      .   0.56   . .       .
     BZD-short:zolpidem 0 1.25      .   1.25   . .       .
    BZD-short:zopiclone 1 1.15   1.18      .   . .       .
   propiomazine:placebo 0 2.22      .   2.22   . .       .
       zolpidem:placebo 1 1.00   1.00      .   . .       .
      zopiclone:placebo 1 1.09   1.06      .   . .       .
  propiomazine:zolpidem 0 2.22      .   2.22   . .       .
 propiomazine:zopiclone 1 2.03   2.03      .   . .       .
     zolpidem:zopiclone 0 0.92      .   0.92   . .       .

Legend:
 comparison - Treatment comparison
 k          - Number of studies providing direct evidence
 nma        - Estimated treatment effect (OR) in network meta-analysis
 direct     - Estimated treatment effect (OR) derived from direct evidence
 indir.     - Estimated treatment effect (OR) derived from indirect evidence
 RoR        - Ratio of Ratios (direct versus indirect)
 z          - z-value of test for disagreement (direct versus indirect)
 p-value    - p-value of test for disagreement (direct versus indirect)
[1] "Percent of comparisons where there is some evidence (p-value<0.05) of disagreement between direct and indirect sources: NaN. (0 out of 0 comparisons)."
[1] "File created by E. G. Ostinelli on 2022-01-02"
